These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 35256324)

  • 21. Immediate Prostate-specific Antigen Decline After Enzalutamide Following Abiraterone Predicts Survival in Castration-resistant Disease.
    Fujimoto N; Minato A; Igawa T; Hiroshige T; Obara W; Fukuda A; Nagata Y; Mizushima Y; Tomisaki I; Harada K
    Anticancer Res; 2022 Jun; 42(6):3041-3047. PubMed ID: 35641266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide.
    Miyake H; Hara T; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
    Urol Oncol; 2017 Jun; 35(6):432-437. PubMed ID: 28188090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience.
    Chang LW; Hung SC; Wang SS; Li JR; Yang CK; Chen CS; Ho HC; Cheng CL; Ou YC; Chiu KY
    Anticancer Res; 2019 Jul; 39(7):3901-3908. PubMed ID: 31262919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate.
    Thomsen FB; Røder MA; Rathenborg P; Brasso K; Borre M; Iversen P
    Scand J Urol; 2014 Jun; 48(3):268-75. PubMed ID: 24255983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
    de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
    Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide.
    Miyake H; Matsushita Y; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
    Med Oncol; 2017 Nov; 34(12):200. PubMed ID: 29164346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.
    Thiery-Vuillemin A; Poulsen MH; Lagneau E; Ploussard G; Birtle A; Dourthe LM; Beal-Ardisson D; Pintus E; Trepiakas R; Lefresne F; Lukac M; Van Sanden S; Pissart G; Reid A;
    Eur Urol; 2020 Mar; 77(3):380-387. PubMed ID: 31594705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer.
    Freedland SJ; Li S; Pilon D; Bhak RH; Narkhede S; Lefebvre P; Young-Xu Y
    Curr Med Res Opin; 2021 Apr; 37(4):635-642. PubMed ID: 33571020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
    Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
    Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer.
    Pilon D; Queener M; Lefebvre P; Ellis LA
    J Med Econ; 2016 Aug; 19(8):777-84. PubMed ID: 27031255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study.
    Li JR; Wang SS; Chen CS; Yang CK; Lu K; Cheng CL; Hung SC; Chen SY; Hsu CY; Chiu KY
    Anticancer Res; 2022 Oct; 42(10):4857-4866. PubMed ID: 36191989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?
    Pereira-Salgado A; Kwan EM; Tran B; Gibbs P; De Bono J; IJzerman M
    Eur Urol Focus; 2021 Jul; 7(4):752-763. PubMed ID: 32273196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer.
    Demirci A; Bilir C; Gülbağcı B; Hacıbekiroğlu İ; Bayoğlu İV; Bilgetekin İ; Koca S; Çınkır HY; Akdeniz N; Gül D; Varım C; Demirci U; Öksüzoğlu B
    Sci Rep; 2021 Jul; 11(1):14131. PubMed ID: 34239026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of BMI and hemoglobin A1c on survival of veterans with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Govindan S; Cheranda N; Riekhof F; Luo S; Schoen MW
    Prostate; 2024 Feb; 84(3):245-253. PubMed ID: 37909677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors.
    Fuerea A; Baciarello G; Patrikidou A; Albigès L; Massard C; Di Palma M; Escudier B; Fizazi K; Loriot Y
    Eur J Cancer; 2016 Jul; 61():44-51. PubMed ID: 27151554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Enzalutamide Rechallenge for Metastatic Castration-Resistant Prostate Cancer.
    Sawazaki H; Kitamura Y; Madoka U; Segawa Y
    Asian Pac J Cancer Prev; 2024 Jun; 25(6):1863-1867. PubMed ID: 38918645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis.
    Schultz NM; Flanders SC; Wilson S; Brown BA; Song Y; Yang H; Lechpammer S; Kassabian V
    Adv Ther; 2018 Oct; 35(10):1639-1655. PubMed ID: 30191463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate.
    Di Stefano RF; Tucci M; Turco F; Samuelly A; Bungaro M; Pisano C; Vignani F; Gallicchio M; Scagliotti GV; Di Maio M; Buttigliero C
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):812-825. PubMed ID: 33603237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
    Khalaf DJ; Annala M; Taavitsainen S; Finch DL; Oja C; Vergidis J; Zulfiqar M; Sunderland K; Azad AA; Kollmannsberger CK; Eigl BJ; Noonan K; Wadhwa D; Attwell A; Keith B; Ellard SL; Le L; Gleave ME; Wyatt AW; Chi KN
    Lancet Oncol; 2019 Dec; 20(12):1730-1739. PubMed ID: 31727538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort study.
    Soleimani M; Zou K; Sunderland K; Struss W; Eigl BJ; Nappi L; Kollmannsberger CK; Finch D; Noonan K; Vergidis J; Zulfiqar M; Chi KN; Khalaf DJ
    Eur J Cancer; 2021 Jul; 152():215-222. PubMed ID: 34130153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.